Mycoalertdetection kit

Manufactured by Merck Group

The MycoAlert Detection Kit is a rapid and sensitive test that detects the presence of mycoplasma contamination in cell cultures. The kit utilizes a bioluminescent enzyme reaction to identify mycoplasma-specific enzymes, providing a reliable method for monitoring cell culture integrity.

Automatically generated - may contain errors

Lab products found in correlation

Mission shrna vectors, by Merck Group (1 mentions)

2 protocols using mycoalertdetection kit

S100A4 Localization in AML Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Diagnostic bone marrow or peripheral blood from AML patients and cord
blood were collected with informed consent; patient clinical characteristics
outlined in Supplemental
Methods. Normal human CD34⁺ cells were isolated as
previously described [17 (link)].
Cell lines were obtained from ECACC™ (Salisbury, UK) or ATCC
(Middlesex, U.K.) and cultured under recommended conditions. The genetic
identity of the cell lines was confirmed by short tandem repeat (STR). Cells at
passages greater than twenty were not used in the experiments performed in this
study. Monitoring for Mycoplasma contamination was performed using the MycoAlert
Detection Kit (Sigma). S100A4 harboring a nuclear localization sequence (NLS)
was expressed utilizing retroviral and lentiviral vectors co-expressing GFP as a
selectable marker (Supplemental Methods). For knock down studies,
Mission^® shRNA vectors based on TRC(1)2-pLKO.5-puro
(S100A4 shRNA and non-mammalian shRNA control) were purchased from
Sigma-Aldrich, Dorset, U.K. CD34⁺ cells and cell lines were
transduced and cultured as previously described [17 (link),18 ].

Alanazi B., Munje C.R., Rastogi N., Williamson A.J., Taylor S., Hole P.S., Hodges M., Doyle M., Baker S., Gilkes A.F., Knapper S., Pierce A., Whetton A.D., Darley R.L, & Tonks A. (2019). Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia, 34(2), 427-440.

+ Open protocol

+ Expand

Characterizing AML and Normal Hematopoietic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Diagnostic bone marrow or peripheral blood from AML patients and cord blood were collected with informed consent; patient clinical characteristics were outlined in Supplementary Methods. Normal human CD34⁺ cells were isolated as previously described [17 (link)].
Cell lines were obtained from ECACC^TM (Salisbury, UK) or ATCC (Middlesex, UK) and cultured under recommended conditions. The genetic identity of the cell lines was confirmed by short tandem repeat (STR). Cells at passages greater than twenty were not used in the experiments performed in this study. Monitoring for Mycoplasma contamination was performed using the MycoAlert Detection Kit (Sigma). S100A4 harboring a nuclear localization sequence (NLS) was expressed utilizing retroviral and lentiviral vectors co-expressing GFP as a selectable marker (Supplementary Methods). For knock down studies, Mission® shRNA vectors based on TRC(1)2-pLKO.5-puro (S100A4 shRNA and nonmammalian shRNA control) were purchased from Sigma-Aldrich, Dorset, U.K. CD34⁺ cells and cell lines were transduced and cultured as previously described [17 (link), 18 (link)].

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!